



March 12, 2013

## **Dendreon Announces Webcast Presentation at ROTH Conference**

SEATTLE--(BUSINESS WIRE)-- March 12, 2013—Dendreon Corporation (NASDAQ:DNDN) today announced that management will present at the 25<sup>th</sup> Annual ROTH Conference in Laguna Niguel, California, on March 18, 2013, at 11:00 a.m. PT.

The presentation will be webcast live and available for replay from Dendreon's website, [www.dendreon.com](http://www.dendreon.com). If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

### **About Dendreon**

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE<sup>®</sup> (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit <http://www.dendreon.com/>.

Dendreon Corporation  
Corporate Communications  
Lindsay Rocco, 862-596-1304  
[media@dendreon.com](mailto:media@dendreon.com)

or  
Dendreon Corporation  
Investor Relations  
Nicole Soley, 206-455-2384  
[InvestorRelations@dendreon.com](mailto:InvestorRelations@dendreon.com)

Source: Dendreon Corporation

News Provided by Acquire Media